VERNAL KERATOCONJUNCTIVITIS MARKET ANALYSIS

Vernal Keratoconjunctivitis Market, by Drug Type (Bertilimumab, Verkazia, Lodoxamide, Tacrolimus, Antolimab, Nomacopan, and Others), by Treatment (Mast Cell Stabilizers, Antihistamines, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Topical Corticosteroids, Cyclosporine, Tacrolimus, and Others), by Dosage Form (Gel, Ointment, Tablet, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Sep 2021
Code : CMI4657
Pages :321
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Vernal Keratoconjunctivitis Market: Restraint

There is no precise diagnostic criteria for vernal keratoconjunctivitis, which is anticipated to hamper the market growth during the forecast period. The vernal keratoconjunctivitis disease's distinctive signs and symptoms are used to detect the diagnosis. Several mild or unusual instances may be undetected as no exact diagnostic criteria is been developed.

Global Vernal Keratoconjunctivitis Market– Impact of Coronavirus (COVID-19) Pandemic

Several clinicians and patients requested better suggestion for the treatment of vernal keratoconjunctivities patients in the COVID-19 pandemic. Most of the patients and doctors were following the recommendations given by scientific societies such as Indian Journal of Ophthalmology. Recently, considering the various difficulties associated with the COVID-19 pandemic, despite the fact that patients require treatments, vernal keratoconjuctivitis has not been prioritised. Topical medicines are the primary line of treatment for types of vernal keratoconjuctivitis with topical corticosteroids added in severe cases of vernal keratoconjunctivitis, even in the patients are at risk of COVID-19.